Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma

Oncotarget
David ChironM Amiot

Abstract

The aggressive biological behavior of mantle cell lymphoma (MCL) and its short response to current treatment highlight a great need for better rational therapy. Herein, we investigate the ability of ABT-199, the Bcl-2-selective BH3 mimetic, to kill MCL cells. Among MCL cell lines tested (n = 8), only three were sensitive (LD50 < 200 nM). In contrast, all primary MCL samples tested (n = 11) were highly sensitive to ABT-199 (LD50 < 10 nM). Mcl-1 and Bcl-xL both confer resistance to ABT-199-specific killing and BCL2/(BCLXL+MCL1) mRNA ratio is a strong predictor of sensitivity. By mimicking the microenvironment through CD40 stimulation, we show that ABT-199 sensitivity is impaired through activation of NF-kB pathway and Bcl-x(L) up-regulation. We further demonstrate that resistance is rapidly lost when MCL cells detach from CD40L-expressing fibroblasts. It has been reported that ibrutinib induces lymphocytosis in vivo holding off malignant cells from their protective microenvironment. We show here for two patients undergoing ibrutinib therapy that mobilized MCL cells are highly sensitive to ABT-199. These results provide evidence that in situ ABT-199 resistance can be overcome when MCL cells escape from the lymph nodes. Altogether,...Continue Reading

References

Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·H H LeeG Cheng
Oct 11, 2002·The EMBO Journal·H J CoopeS C Ley
May 3, 2008·Cancer Research·Christin TseSteven W Elmore
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lee A HonigbergJoseph J Buggy
Aug 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Cyrille TouzeauSteven Le Gouill
Dec 1, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jacqueline M TrompEric Eldering
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew W RobertsRod Humerickhouse
Aug 10, 2012·The New England Journal of Medicine·H C Kluin-NelemansM H Dreyling
Oct 2, 2012·The Journal of Clinical Investigation·Pedro JaresElias Campo
Feb 16, 2013·Cancer Cell·Matthew S Davids, Anthony Letai
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
May 27, 2014·Current Opinion in Hematology·Nakhle Saba, Adrian Wiestner

❮ Previous
Next ❯

Citations

Dec 23, 2015·Expert Review of Hematology·Layal El HalabiVincent Ribrag
Feb 1, 2017·Leukemia & Lymphoma·Prithviraj BoseMarina Konopleva
Jan 29, 2020·Current Oncology Reports·Luke FletcherAlexey Danilov
Mar 24, 2018·International Journal of Molecular Medicine·Zewu Dong, Yufang Yuan
Jun 26, 2015·Oncotarget·Arnau MontravetaDolors Colomer
Aug 5, 2018·Leukemia·Cyrille TouzeauPhilippe Moreau
Apr 24, 2020·Expert Opinion on Investigational Drugs·Clémentine Sarkozy, Vincent Ribrag
Sep 2, 2016·Science Translational Medicine·Jessica T LeonardBill H Chang
Jun 24, 2017·Journal of Experimental & Clinical Cancer Research : CR·Zhong ZhengWei-Li Zhao
Jan 24, 2018·British Journal of Haematology·Oshrat Hershkovitz-RokahOfer Shpilberg
May 10, 2017·Expert Review of Anticancer Therapy·David Tucker, Simon Rule
Jul 18, 2018·Blood·Rebecca ValentinMatthew S Davids
Mar 19, 2020·Cells·Maxime JullienCyrille Touzeau
Oct 25, 2017·The Biochemical Journal·Astrid Ruefli-Brasse, John C Reed
Sep 1, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Clare M AdamsChristine M Eischen
Apr 22, 2017·Molecular Cancer Therapeutics·Hsu-Ping KuoBetty Y Chang
Jun 2, 2017·Cancer Research·Shyril O'SteenOliver W Press
Nov 4, 2020·Cell Death & Disease·Isha KapoorAlexandru Almasan
Aug 31, 2020·Hematology/oncology Clinics of North America·Rory McCullochSimon Rule

❮ Previous
Next ❯

Methods Mentioned

BETA
gradient density centrifugation
FCS
flow cytometry

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.